Search results
Eli Lilly and Company (NYSE:LLY) PT Raised to $957.00 at Jefferies Financial Group
ETF DAILY NEWS· 20 hours agoEli Lilly and Company (NYSE:LLY – Get Free Report) had its price target upped by investment analysts at Jefferies Financial Group from $925.00 to $957.00 ...
Eli Lilly’s Alzheimer’s drug to face safety, dosing scrutiny from FDA advisers
Market Watch· 2 days agoIn a briefing document prepared for the advisory committee, the FDA raised questions about a unique...
Dow Jones Futures: Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events
Investor's Business Daily· 7 minutes agoA big Apple AI push, the Tesla shareholder meeting and the latest Federal Reserve rate outlook "dot...
Biogen stock favored at RBC as Lilly awaits Alzheimer’s drug
Seeking Alpha· 4 days agoRBC Capital Markets maintains a bullish view on Biogen (BIIB) despite Eli Lilly's (LLY) upcoming FDA...
Barclays bullish on Eli Lilly stock with positive outlook By Investing.com
Investing.com· 6 days agoOn Monday, Barclays (LON:BARC) expressed a positive stance on Eli Lilly (NYSE:LLY) stock,...
Eli Lilly CFO Anat Ashkenazi to resign (NYSE:LLY)
Seeking Alpha· 4 days agoEli Lilly's CFO, Anat Ashkenazi, has resigned after over two decades with the company to explore opportunities outside the pharmaceutical industry.
Eli Lilly details NASH effects of weight loss drug (NYSE:LLY)
Seeking Alpha· 4 days agoEli Lilly (LLY) posts detailed mid-stage results highlighting the benefits of its weight loss drug...
Eli Lilly Is Trading At A Record High Ahead Of A Key FDA Meeting — Is It A Buy?
Investor's Business Daily· 2 days agoEli Lilly stock is trading at a record high as enthusiasm grows for its Alzheimer's treatment,...
Eli Lilly finance chief to join Alphabet
Reuters· 4 days agoEli Lilly said on Wednesday its chief financial officer Anat Ashkenazi has resigned after more than two decades at the U.S. drugmaker.
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients...
StreetInsider· 12 hours agoEli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate ...